Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
J Pediatr ; 163(1 Suppl): S4-7, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23773593

ABSTRACT

OBJECTIVE: Haemophilus influenzae type b (Hib) conjugate vaccine was first introduced in Africa in The Gambia in 1997 as a primary 3-dose course in infancy with no booster, and was followed by the disappearance of invasive Hib disease by 2002. A cluster of cases detected non-systematically in post-infant children in 2005-2006 raised the question of the need for a booster dose. The objective of this study was to determine the incidence of invasive Hib disease in Gambian children 14 years after the introduction of Hib conjugate vaccine. STUDY DESIGN: This hospital-based clinical and microbiological Hib disease surveillance in 3 hospitals in the western region of The Gambia was undertaken between October 2007 and December 2010 applying the same methods used in a previous Hib vaccine effectiveness study in 1997-2002. RESULTS: The annual incidences of Hib meningitis and all invasive Hib disease in children aged <5 years remained below 5 cases per 100,000 children during 2008-2010. The median age of patients with any invasive Hib disease was 5 months. CONCLUSION: Hib conjugate vaccination as a primary 3-dose course in The Gambia remains highly effective in controlling invasive Hib disease, and current data do not support the introduction of a booster dose.


Subject(s)
Haemophilus Vaccines/administration & dosage , Haemophilus influenzae type b/immunology , Meningitis, Haemophilus/epidemiology , Bacterial Capsules/immunology , Female , Gambia/epidemiology , Haemophilus Vaccines/immunology , Humans , Incidence , Infant , Male , Meningitis, Haemophilus/prevention & control , Vaccines, Conjugate/administration & dosage , Vaccines, Conjugate/immunology
SELECTION OF CITATIONS
SEARCH DETAIL